Teva Pharmaceutical Industries' quarterly profit beat estimates by two cents and the company reaffirmed its outlook for 2020 despite uncertainty generated by the COVID-19 crisis.
The company also released with Regeneron Pharmaceuticals results for advanced trials for pain medication fasinumab. They said primary endpoints were achieved with a 1 mg monthly dose, demonstrating "significant improvements in pain and physical function over placebo at week 16 and week 24".
Teva CEO Kare Schultz said the companies were still waiting for more safety data.
"Assuming that we get good long-term data that we will be reporting probably in the beginning of next